Supply Chain Council of European Union | Scceu.org
News

In the footsteps of AstraZeneca, Novartis commits to carbon-neutral supply chain by 2030 – Endpoints News

Fol­low­ing in As­traZeneca’s car­bon-re­duced foot­steps, No­var­tis an­nounced new sus­tain­abil­i­ty tar­gets on Tues­day, which in­clude plans to neu­tral­ize sup­ply chain emis­sions in the next 10 years.

The Swiss phar­ma aims to be car­bon-neu­tral in its own op­er­a­tions by 2025, and across its sup­ply chain by 2030. To get there, it says it will re­duce ab­solute emis­sions by 35% across its val­ue chain, and fol­low a “dual strat­e­gy” to de­crease en­er­gy and fu­el con­sump­tion, im­prove ef­fi­cien­cy and adopt re­new­able en­er­gy sources. It au­dit­ed all ma­jor sites for po­ten­tial im­prove­ments.

“We have a long­stand­ing, com­pre­hen­sive en­er­gy and cli­mate pro­gram, which aims to im­prove en­er­gy ef­fi­cien­cy for all in­dus­tri­al and com­mer­cial op­er­a­tions and use re­new­able en­er­gy sources where avail­able and fea­si­ble,” the com­pa­ny stat­ed.

No­var­tis tout­ed what it’s al­ready do­ing to pre­serve the en­vi­ron­ment, in­clud­ing se­ques­ter­ing car­bon through forestry projects in Colom­bia, Mali, Chi­na and Ar­genti­na. It plant­ed 800 hectares of trees at the San­to Domin­go Es­tate in Ar­genti­na in 2007, then added 2,250 hectares in the fol­low­ing three years. By 2040, the com­pa­ny ex­pects to col­lect up to 2 mil­lion tons of car­bon diox­ide equiv­a­lents through the project. It al­so boast­ed of its Texas wind farm, and says it has sim­i­lar plans to achieve green en­er­gy in Eu­rope.

“Af­ter the suc­cess­ful com­ple­tion of a re­new­able pow­er pur­chase agree­ment in the US that achieved car­bon neu­tral­i­ty in that mar­ket for pro­cured elec­tric­i­ty we are now ac­tive­ly pur­su­ing a pan-Eu­ro­pean pow­er pur­chase agree­ment that will achieve the same, de­car­boniz­ing our pur­chased elec­tric­i­ty in one of our largest re­gions of op­er­a­tions and elim­i­nat­ing tran­si­tion risk as­so­ci­at­ed with car­bon pric­ing,” No­var­tis’ CDP cli­mate change in­for­ma­tion re­quest states.

The an­nounce­ment comes about 7 months af­ter UK-based As­traZeneca com­mit­ted to achiev­ing neg­a­tive car­bon emis­sions across its val­ue chain by 2030. The com­pa­ny will in­vest up to $1 bil­lion in its “Am­bi­tion Ze­ro Car­bon” strat­e­gy, which in­cludes us­ing re­new­able en­er­gy for pow­er and heat, and switch­ing to a 100% elec­tric ve­hi­cle fleet five years ahead of sched­ule.

“Cli­mate change is an ur­gent threat to pub­lic health, the en­vi­ron­ment and the sus­tain­abil­i­ty of the glob­al econ­o­my. Since 2015, we have re­duced our car­bon emis­sions from op­er­a­tions by al­most a third and our wa­ter con­sump­tion by al­most one fifth,” As­traZeneca CEO Pas­cal So­ri­ot said in a state­ment.

Related posts

NASEM report urges medical supply chain transparency, agility

scceu

How To Financially Prepare for Future Supply Chain Disruptions

scceu

A Digitalized Food Supply Chain

scceu